# Aqtual, Inc.

> Aqtual, Inc. is a Hayward, California precision medicine company that reads epigenetics, gene regulation and transcriptomics from a single blood draw. Its proprietary active-chromatin cell-free DNA (cfDNA) platform captures circulating chromatin to survey hundreds of thousands of regulatory sites, integrating DNA, epigenetic regulation and protein-DNA binding in one blood-based assay. The company is first commercializing a test that predicts which therapy will work for rheumatoid arthritis patients, with a broader pipeline spanning oncology, immunology, cardiovascular, metabolic and neurological disease. Aqtual has raised roughly $47M to date, including a $31M Series B in July 2025.

- **Founded:** 2018
- **Headquarters:** Hayward, California, United States
- **Founders:** Diana Abdueva (Founder & CEO), Rich Rava (Co-Founder & Chief Technology Officer)
- **Team size:** ~32 employees
- **Products:** Active Chromatin cfDNA Platform, Rheumatoid Arthritis Therapy Response Test, Oncology & Chronic Disease Pipeline
- **Notable:** Raised approximately $47M total, including an oversubscribed $31M Series B in July 2025., Built the first cfDNA assay to integrate DNA, epigenetic regulation and protein-DNA binding in a single blood draw., Enrolled 1,300+ patients in the PRIMA-102 rheumatoid arthritis trial, delivering initial proof-of-concept data.

## Products & services

- **Active Chromatin cfDNA Platform** — Proprietary technology that captures and analyzes circulating chromatin to measure epigenetics, gene regulation and transcriptomics from cell-free DNA in a single blood draw - surveying 200,000 gene promoters, 400,000 enhancers, 50,000 insulators, 20,000 silencers and 1 million transcription-factor binding sites. First to integrate DNA, epigenetic regulation and protein-DNA binding in one blood-based assay.
- **Rheumatoid Arthritis Therapy Response Test** — Flagship product: a blood test to guide therapy management in rheumatoid arthritis by identifying biomarkers associated with treatment response, aiming to predict which drug class will work for a given patient. Validated through the PRIMA-102 clinical trial (NCT05936970).
- **Oncology & Chronic Disease Pipeline** — Biomarker discovery and disease-monitoring assays extending the platform across oncology, immunology, cardiovascular, metabolic and neurological conditions for detection, monitoring and patient stratification.

## Achievements

- Raised approximately $47M total, including an oversubscribed $31M Series B in July 2025.
- Built the first cfDNA assay to integrate DNA, epigenetic regulation and protein-DNA binding in a single blood draw.
- Enrolled 1,300+ patients in the PRIMA-102 rheumatoid arthritis trial, delivering initial proof-of-concept data.
- Platform surveys over 1 million transcription-factor binding sites and hundreds of thousands of regulatory elements from blood.
- Emerged from stealth in 2023 after years of R&D (formerly BloodQ).

## Latest updates

- **2025-07** — Raised over $30M ($31M) in an oversubscribed Series B led with new investors Bold Capital and Bold Longevity Growth Fund to scale its cfDNA platform and commercialize its rheumatoid arthritis therapy-response test.
- **2025-07** — PRIMA-102 trial surpassed 1,300 enrolled patients with initial proof-of-concept data; completion expected Q4 2025.
- **2024-05** — Appointed new medical, translational research and data-integrity executives, including Maggie Louie as VP of Translational Research and Strategic Partnerships.
- **2023-10** — Emerged from stealth with a $16M Series A co-led by Genoa Ventures, Manta Ray Ventures and Yu Galaxy; initiated rheumatoid arthritis clinical trial.

## Links

- Website: https://aqtual.com
- LinkedIn: https://www.linkedin.com/company/aqtual

---

Profile page: https://yespress.io/aqtual-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-13